What's Happening?
Scientists at the University of Southern California (USC) have developed a method to create a renewable and expandable supply of immune cell precursors, which could significantly advance cancer immunotherapy. The study, published in the journal Cell,
focuses on granulocyte-monocyte progenitors (GMPs), which are progenitor cells that produce macrophages and other immune cells. These cells play a crucial role in defending the body against infections and have potential as tools for cancer treatment. The researchers demonstrated that GMPs can be extensively expanded in the lab and genetically modified to recognize cancer cells, enhancing broader immune responses. This development introduces a scalable and engineerable platform for cellular immunotherapy, with implications for both cancer treatment and stem cell biology.
Why It's Important?
The development of a renewable supply of immune cell precursors is a significant advancement in the field of cancer immunotherapy. Macrophages, which are derived from GMPs, naturally infiltrate tumors and consume cancer cells, making them promising candidates for cancer treatment. However, mature macrophages are challenging to grow in large numbers and genetically engineer. The ability to expand and engineer GMPs overcomes these obstacles, offering a scalable starting point for developing cell therapies for cancer and other conditions. This breakthrough could lead to more effective treatments for solid tumors, which have been difficult to target with existing therapies.
What's Next?
The research team plans to further explore the potential applications of GMPs beyond oncology. The platform may be used to treat immune deficiencies and other conditions. The study suggests that the future of immunotherapy may depend on selecting the right developmental stage of the cell, in addition to designing better chimeric antigen receptors (CARs). The researchers are also considering the possibility of creating off-the-shelf therapies that can be produced in advance and used in multiple patients, rather than generating custom treatments for each individual.
